Insider · CIK 0001649119
Yujiro S Hata
Files at ENTA (ENANTA PHARMACEUTICALS INC), IDYA (IDEAYA Biosciences, Inc.). First filing Oct 8, 2026, latest Oct 8, 2026.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
IDYA: IDEAYA Biosciences, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | IDEAYA Biosciences, Inc. | $985k 26,338 shares | -4% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | IDYA IDEAYA Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +26,338 | $4.31 | $114k | 717,033 | 4 d ago |
| Oct 6, 2026 | IDYA IDEAYA Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -25,538 | $37.39 | $955k | 691,495 | 4 d ago |
| Oct 6, 2026 | IDYA IDEAYA Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -800 | $38.26 | $31k | 690,695 | 4 d ago |
| Oct 6, 2026 | IDYA IDEAYA Biosciences, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -26,338 | $0.00 | $0 | 23,116 | 4 d ago |
| Mar 13, 2025 | ENTA ENANTA PHARMACEUTICALS INC | AGrant or award Stock Option (right to buy)derivative | +15,700 | $0.00 | $0 | 15,700 | Mar 14, 2025 |
| Feb 27, 2025 | IDYA IDEAYA Biosciences, Inc. | AGrant or award Stock Option (right to buy)derivative | +600,000 | $0.00 | $0 | 600,000 | Feb 28, 2025 |
| Feb 18, 2025 | IDYA IDEAYA Biosciences, Inc. | MOption exercise Common Stock | +12,808 | $19.52 | $250k | 690,695 | Feb 19, 2025 |
| Feb 18, 2025 | IDYA IDEAYA Biosciences, Inc. | MOption exercise Stock Option (right to buy)derivative | -12,808 | $0.00 | $0 | 182,192 | Feb 19, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.